Skip to main content

Share story

AI

Apple plans to turn Siri into full AI chatbot

Apple plans to turn Siri into full AI chatbot Image: Primary
Apple is preparing to transform its Siri assistant into a chatbot resembling ChatGPT, according to a report by Bloomberg's Mark Gurman. The feature, codenamed Campos internally, would handle both voice and text queries and is slated for integration with iOS 27. The update is positioned to be a highlight at the company's WWDC event in June. Senior vice president Craig Federighi had earlier indicated a desire to avoid chatbot functionality in favor of more seamlessly integrated AI tools. The revised approach follows the strong performance of rival chatbot offerings. Apple had previously postponed enhancements to make Siri more personalized and had evaluated AI technology from OpenAI and Anthropic. The company ultimately partnered with Google on its Gemini model, a deal confirmed earlier this month. It is also aware of OpenAI's hardware ambitions, which involve former Apple executive Jony Ive.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from TechCrunch and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.